Barclays Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $16
Barclays analyst Balaji Prasad maintains $Evolus(EOLS.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 46.3% and a total aver
Barclays Reaffirms Their Buy Rating on Evolus (EOLS)
Strong Buy Rating for Evolus Backed by Growth Potential and Market Penetration Prospects
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
Evolus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 101.19% HC Wainwright & Co. → $27 Reiterates Buy → Buy 05/08/2024 101.19% HC Wainwright & Co. →
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)
Express News | Evolus Dermal Filler Evolysse Lift Meets Primary Endpoint, Demonstrates Superiority To Restylane-L At 6 Months; Shows Statistically Significant Improvement In Nasolabial Fold Severity Compared To Restylane-L At All Timepoints Over 12 Months
Evolus Announces Positive Data From Pivotal Trial for First Two Evolysse Dermal Filler Products at 2024 SCALE Meeting
Evolus dermal filler, Evolysse Lift, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months; Secondary endpoints for improvement in nasolabial fold severity s
Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS)
Evolus(EOLS.US) Director Sells US$362.01K in Common Stock
$Evolus(EOLS.US)$ Director Malik Vikram sold 28,000 shares of common stock on May 13, 2024 at an average price of $12.929 for a total value of $362.01K.Source: Announcement What is statement of change
Evolus(EOLS.US) Director Sells US$131.01K in Common Stock
$Evolus(EOLS.US)$ Director GILL DAVID N sold 10,361 shares of common stock on May 13, 14, 2024 at an average price of $12.6445 for a total value of $131.01K.Source: Announcement What is statement of c
Evolus Celebrates Fifth Anniversary of Launching Its Flagship Product Jeuveau at the Women's Wear Daily Beauty CEO Summit
David Moatazedi, President and Chief Executive Officer of Evolus, is first medical aesthetics leader to be a speaker at WWD Beauty CEO Summit Evolus' flagship product, Jeuveau is the fastest growing
Form 144 | Evolus(EOLS.US) Director Proposes to Sell 362.04K in Common Stocks
SEC FILLINGS DISCLOSED/ May 14, $Evolus(EOLS.US)$ Director Malik Vikram intends to sell 28,000 shares of its common stock on May 13, with a total market value of approximately $362.04K. Source: Ann
Form 144 | Evolus(EOLS.US) Director Proposes to Sell 131.58K in Common Stocks
SEC FILLINGS DISCLOSED/ May 13, $Evolus(EOLS.US)$ Director GILL DAVID N intends to sell 10,361 shares of its common stock on May 13, with a total market value of approximately $131.58K. Source: Ann
Barclays Keeps Their Buy Rating on Evolus (EOLS)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
Evolus's Strong Q1 Performance and Solid Growth Trajectory Justify Buy Rating
Evolus Outperforms Expectations With Strong Q1 Sales and Promising Growth Trajectory
Evolus First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags